Published online Nov 28, 2005. doi: 10.3748/wjg.v11.i44.6975
Revised: November 15, 2004
Accepted: November 19, 2004
Published online: November 28, 2005
AIM: To construct the recombinant Lactococcus lactis as oral delivery vaccination against malaria.
METHODS: The C-terminal 19-ku fragments of MSP1 (MSP-119) of Plasmodium yoelii 265-BY was expressed in L. lactis and the recombinant L. lactis was administered orally to BALB/c and C57BL/6 mice. After seven interval vaccinations within 4 wk, the mice were challenged with P. yoelii 265-BY parasites of erythrocytic stage. The protective efficacy of recombinant L. lactis was evaluated.
RESULTS: The peak parasitemias in average for the experiment groups of BALB/c and C57BL/6 mice were 0.8±0.4% and 20.8±26.5%, respectively, and those of their control groups were 12.0±0.8% and 60.8±9.6%, respectively. None of the BALB/c mice in both experimental group and control group died during the experiment. However, all the C57BL/6 mice in the control group died within 23 d and all the vaccinated mice survived well.
CONCLUSION: The results imply the potential of recombinant L. lactis as oral delivery vaccination against malaria.